Skip to main content
SPT logo

SPT — Investor Relations & Filings

Ticker · 1789 ISIN · TW0001789006 TW Manufacturing
Open in API
Filings indexed 2,243 across all filing types
Latest filing 2026-06-10 AGM Information
Country TW Taiwan
Listing TW 1789

About SPT

https://www.scinopharm.com/tw

ScinoPharm Taiwan, Ltd. is a global provider of high-quality Active Pharmaceutical Ingredients (APIs) and comprehensive Contract Development and Manufacturing Organization (CDMO) services. The company specializes in process research, development, and cGMP production, maintaining a leadership position in oncology APIs. Its portfolio covers therapeutic areas including cancer, hematology, metabolic disorders, and central nervous system diseases. ScinoPharm offers one-stop solutions encompassing peptide synthesis, API process development, and the manufacturing of sterile injectables and complex generics. The company is distinguished by its expertise in high-barrier pharmaceutical technologies and adherence to stringent international regulatory standards, such as the U.S. FDA. Serving both generic and innovative drug sectors, it leverages advanced R&D and integrated manufacturing to support global healthcare markets.

Recent filings

Filing Released Lang Actions
115年年報及股東會資料 — 2026_1789_20260527FE3.pdf
AGM Information Classification · 95% confidence The document is the official minutes of the 2026 Annual General Shareholders’ Meeting, detailing convening information, agendas, reports presented, proposals voted on (business report, financial statements, earnings distribution, amendments to articles, operational procedures, non-compete releases), and complete voting results. This clearly constitutes AGM materials/minutes rather than a regulatory notice, financial report, or proxy statement. Therefore, it is classified as AGM Information (AGM-R).
2026-06-10 English
115年年報及股東會資料 — 2026_1789_20260527F05.pdf
AGM Information Classification · 85% confidence The document is the complete minutes (議事錄) of the company’s Annual General Meeting (股東常會) held on 27 May 2024, including the agenda, reports, resolutions, voting tallies, and attached AGM materials (annual operating report, audit committee report, audited financial statements, etc.). This corresponds to AGM Information (AGM-R), which covers materials and presentations used or distributed at the AGM (rather than the standalone Annual Report or merely a voting-results notice).
2026-06-10 Chinese
115年05月內部人持股異動(事後)
Director's Dealing Classification · 65% confidence The document is a Taiwanese public information disclosure (“公開資訊觀測站”) detailing the shareholdings of company insiders (chairman, directors, independent directors, general manager, etc.), showing their beginning balances, monthly changes, and ending balances. This is a classic insider shareholding disclosure, fitting the “Director’s Dealing” (insider trade/holding) category rather than a full report or announcement of another type.
2026-06-08 Chinese
115年05月董事會成員及持股
Regulatory Filings Classification · 82% confidence The document is a detailed disclosure of insider holdings and pledged shares for directors, independent directors, and senior management of the company as filed on the public information observation platform. It does not report a specific share transaction (no trades, purchases, or sales) and is not a capital change, dividend notice, M&A, or similar. It is a routine regulatory disclosure with no dedicated specialized category other than the general regulatory announcements. Therefore, under the classification scheme, it falls into the fallback category Regulatory Filings (RNS).
2026-06-08 Chinese
115年06月法人說明會簡報 — 178920260604E001.pdf
Investor Presentation Classification · 95% confidence The document is a slide presentation titled ‘ScinoPharm Investor Conference’ with forward‐looking disclaimers, agenda, business updates, strategy slides, and detailed Q1 financial performance tables, charts, and a Q&A section. It is clearly an investor presentation deck rather than an earnings release, regulatory filing, or annual/interim report. Therefore, it is classified as an Investor Presentation (IP).
2026-06-04 English
115年06月法人說明會簡報 — 178920260604M001.pdf
Investor Presentation Classification · 92% confidence The document is a slide deck titled “台灣神隆法人說明會” dated June 4, 2026 and includes corporate overview, business updates, detailed Q1 financial statements, charts, and Q&A—classic elements of an investor presentation. It is not a regulatory announcement or mere report publication notice, but a full presentation aimed at institutional investors. Therefore it fits the Investor Presentation category.
2026-06-04 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.